Lilly(US:LLY) ZACKS·2025-09-09 00:37Core Viewpoint - Eli Lilly is experiencing significant stock appreciation and is expected to report strong earnings and revenue growth in its upcoming earnings disclosure Group 1: Stock Performance - Eli Lilly's stock increased by 1.51% to $738.17, outperforming the S&P 500's daily gain of 0.21% [1] - Over the past month, Eli Lilly's shares have appreciated by 16.23%, compared to the Medical sector's gain of 5.47% and the S&P 500's gain of 3.07% [1] Group 2: Earnings and Revenue Estimates - Analysts expect Eli Lilly to post earnings of $6.42 per share, reflecting a year-over-year growth of 444.07% [2] - The revenue forecast for the upcoming quarter is $16.05 billion, indicating a 40.32% growth compared to the same quarter last year [2] - For the full year, earnings are projected at $23.03 per share and revenue at $61.81 billion, representing changes of +77.29% and +37.22% from the prior year, respectively [3] Group 3: Analyst Estimates and Rankings - Changes in analyst estimates for Eli Lilly are crucial as they reflect the evolving business trends and analysts' confidence in the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Eli Lilly at 3 (Hold) [6] Group 4: Valuation Metrics - Eli Lilly has a Forward P/E ratio of 31.58, which is a premium compared to the industry average of 14.41 [7] - The company holds a PEG ratio of 1.02, compared to the industry average PEG ratio of 1.37 [7] Group 5: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 160, placing it in the bottom 36% of all industries [8]